Navigation Links
Aviir, Inc.'s CEO Dr. Douglas Harrington Delivered The Facts Surrounding Heart Disease At The Los Angeles Ultimate Women's Expo
Date:11/4/2012

IRVINE, Calif., Nov. 4, 2012 /PRNewswire/ -- Dr. Douglas Harrington, CEO of Aviir, Inc., joined a host of influential companies and experts at the Los Angeles Ultimate Women's Expo on Saturday, October 27 to discuss America's leading threat to women: Heart Disease. Dr. Harrington's lecture "Everything You Ever Wanted to Know About Heart Disease But Were Afraid to Ask" provided a higher level of insight into the disease and how women can empower themselves, improving their cardiovascular health.  The speaking session began at 12:30 PM, at the Los Angeles Convention Center and was sponsored by GuardaHeart Foundation.

(Photo: http://photos.prnewswire.com/prnh/20121104/LA05795 )

As CEO of Aviir, Inc., Dr. Harrington brings more than 25 years of experience in the commercialization of health care technology. Aviir, Inc. is an Irvine-based biotechnology company that develops innovative diagnostic and laboratory tests. Dr. Harrington's personal mission is to offer clarity to heart disease through reliable assessments and prevention.

The Los Angeles Ultimate Women's Expo sought out some of the best seminar speakers around the world to participate in their event, which is held in several cities across the country.

GuardaHeart sponsors heart risk assessments through an on-going collaboration with Aviir.  Far too many lives continue to be needlessly lost to heart disease, while many more are burdened with the medical debt caused by surviving a heart attack.

"Heart Disease remains the leading cause of death in the US, claiming almost 600,000 lives each year, yet many are unaware that 80% of heart disease is preventable through lifestyle modification," said Dr. Harrington.  Through GuardaHeart's movement "Pledge to SaveThe1" individuals are empowered and equipped to make these critical lifestyle modifications.

Dr. Harrington also discussed an innovative blood test, developed through an Aviir/Stanford University cardiology collaboration, which identifies an individuals' cardiac risk in a five-year timeframe.  "This timeframe allows preventive measures to be implemented," continued Dr. Harrington. "Our mission is to improve healthcare and encourage timely preventive strategies by providing this unique medical information."

About Aviir, Inc.
Aviir was founded in 2005 by cardiologists and scientists from the Stanford University School of Medicine to focus on discovery, development and commercialization of innovative diagnostic tests. The biotechnology company specializes in developing proprietary diagnostic tests that will assist in identifying patients that are truly at high risk for the development of a cardiac event. Aviir's proprietary MIRisk and TruRisk assessments objectively identify, by a simple blood draw, individuals who are at a high risk of a cardiac event over the next five years.  Aviir's CLIA laboratory (Irvine, CA) complements these novel tests with a wide range of additional tests for risk assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders – including pharmacogenomic and genetic tests. The company has adopted a unique clinical laboratory service model to provide physicians better diagnostic tools that improve cardiovascular health of their patients. The company is privately owned and funded by leading life science venture capital firms. Please visit www.aviir.com for more information.

About Los Angeles Ultimate Women's Expo
The Ultimate Women's Expo unites thousands of women with the most respected companies and brands that provide valuable products and services designed to enrich the lives of women. Indulge with the very best Los Angeles has to offer in shopping, fashion, food, entertainment, cosmetics, health and wellness and travel. Expo hours are October 27 and 28 from 10:00 AM. For more information, visit: http://www.lawomensexpo.com.

For media inquiries, please contact: Dina Scaglione (949) 398-6320 dina.scaglione@aviir.com

For Interviews at the Expo please contact:
Yvette Morales
YM & Associates
PR | Marketing | Branding | Business Development
California | New York
949.244.9769 | 310.499.0906 Fax
YMoralesY@YM-PR.com
YM-PR.com
Twitter: @YMTheBevHillsPR


'/>"/>
SOURCE Aviir, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BioHealth Innovation, Inc. Appoints Qiagens Douglas Liu to Board of Directors
2. Uncertainty Surrounding How to Optimize Laboratory Services?
3. University of Kentucky Medical Center Transplants States 1st SynCardia Total Artificial Heart Patient
4. Heart Failure Society of America Annual Meeting To Feature Several Satellite Symposia
5. NIH media availability: Protein linked to increased risk of heart failure and death in older adults
6. Heartland Plant Innovations Wins Kansas Bioscience Authority Funding
7. First Baby With Artificial Heart in Japan
8. Mending a broken heart -- with a molecule that turns stem cells into heart cells
9. Published Findings In Human Gene Therapy Methods Journal Demonstrate Cardiums New Catheter-Based Method Significantly Boosts Gene Delivery To The Heart
10. The PROOF Centre of Excellence Partners with OriGene Technologies on Heart & Kidney Transplant Biomarker Program
11. Top 10 “Best Children’s Hospitals” Include 3 Pediatric Centers Offering SynCardia Total Artificial Heart
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb. 17, 2017  If only one ... had a mutation-conferring resistance to chemotherapy, thousands of ... research has focused on finding these mutations in ... from circulating tumor DNA in blood — to ... therapeutics. Unfortunately, however, detecting these genetic ...
(Date:2/16/2017)... 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company ... better treatment for triple negative breast cancer (TNBC), announced today ... program. The YEi Start in ... help entrepreneurs grow their business in France ... companies selected to complete an intensive one week immersion in ...
(Date:2/16/2017)... LOS ANGELES , Feb. 16, 2017 /PRNewswire/ ... CAPR ), a clinical-stage biotechnology company developing first-in-class ... today announced that it has elected to terminate ... to natriuretic peptide receptor agonists, including Cenderitide. ... a strategic move as we prioritize our efforts ...
(Date:2/16/2017)... HACKENSACK, N.J. , Feb. 16, 2017  Champions ... engaged in the development and sale of advanced technology ... of oncology drugs, today announced the addition of new ... These new models will expand Champions, product ... cancer, head and neck cancer, AML, and non-small cell ...
Breaking Biology Technology:
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... 2021 from $8.3 billion in 2016 at a compound ... 2021. Report Includes - An overview of the ... trends, with data from 2015 and 2016, and projections ... Segmentation of the market on the basis of product ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute announced ... Larry Schlesinger as the Institute,s new President and ... effective May 31, 2017. He is currently the Chair of ... the Center for Microbial Interface Biology at Ohio State University. ... the new President and CEO of Texas Biomed," said Dr. ...
(Date:2/1/2017)... IDTechEx Research, a leading provider of independent ... availability of a new report, Sensors for Robotics: Technologies, Markets ... ... ... IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027: Machine ...
Breaking Biology News(10 mins):